武汉友芝友生物制药股份有限公司于2026年4月8日发布截至2026年3月31日的股份变动月报表。月报显示，公司于报告期内完成非上市股份转换为H股的相关工作，股本结构随之发生明显变动。
根据公告，报告期内H股数量由此前的111,468,814股增至179,479,113股，增加部分为68,010,299股；与此同时，内资股数量从75,510,642股降至14,370,087股，非上市外资股则由6,869,744股降至0。公司在完成上述转换后，截至3月底的法定注册资本合计为193,849,200股，标志着H股全流通顺利完成。
截至本报告期末，公司并无新增发行、购回或注销股份的记录。就期权及权益激励方面，月报中显示此前已通过的2024年H股购股权计划维持生效状态，月度内未披露新增行权或取消情况。
公司在公告中同时确认，截至3月底，已遵守香港联交所上市规则的相关规定。该份公告由联席公司秘书郑建华签署并对所披露信息的准确性和完整性承担责任。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.